Pizzuti Dana's Form 4 filing
Crinetics Pharmaceuticals, Inc. (CRNX) · filed Apr 5, 2023
- Accession no.
- 0001209191-23-023469
- Filed
- Apr 5, 2023
- Trade date
- Apr 3-5, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $132.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pizzuti DanaCIK 0001948238 | Officer (Chief Development Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the number of shares of common stock withheld by the Issuer to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units granted on September 30, 2022. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
Referenced by the price of 1 transaction in Table I.
- F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $16.15 per share. The range of sales prices on the transaction date was $15.82 to $16.40 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.